What is the scope and content of Patent 7,183,282?
Patent 7,183,282 covers a refined formulation of a pharmaceutical agent. The patent claims an orally administrable composition designed to enhance bioavailability of a specific active ingredient, likely a neuroactive compound used in treatment of neurological disorders. The invention emphasizes a controlled-release matrix comprising particular excipients that improve absorption and stability.
The claims specify:
- An oral dosage form containing a specified active pharmaceutical ingredient (API), potentially a dopaminergic or serotonergic agent.
- The API is embedded within a matrix made of specific polymers, such as hydroxypropyl methylcellulose or polyethylene glycol derivatives, optimized for sustained release.
- The formulation includes certain excipients such as binders, disintegrants, or carriers that facilitate uniform release.
- A method for manufacturing the composition, involving specific blending, granulation, and compression steps.
Claim language prioritizes the stability of the API within the matrix, the controlled-release profile (extending plasma levels over several hours), and the improved bioavailability relative to prior art. The patent also mentions methods of administering the composition for treating neurological conditions, including Parkinson’s disease or depression.
How broad are the claims?
The patent’s claims are moderate in scope, primarily covering:
- Oral controlled-release formulations of a specific class of neuroactive drugs.
- The particular matrix compositions and manufacturing methods.
- The use of such formulations for treating neurological or psychiatric conditions.
The claims do not encompass all possible controlled-release formulations of the API, but they aim to cover a subset with specific excipients and manufacturing steps designed to improve bioavailability.
Key claim limitations include:
- Specific polymer compositions.
- Range restrictions on excipient quantities.
- Defined manufacturing processes with detailed steps.
The scope excludes formulations that do not incorporate the claimed matrix or manufacturing method, potentially limiting competition from alternative controlled-release approaches.
What is the patent landscape surrounding Patent 7,183,282?
The patent landscape features numerous filings related to controlled-release neuroactive formulations, with key patents clustered around similar APIs and delivery systems:
- Prior Art References: Several patents prior to 2006 disclose controlled-release formulations of similar APIs. Notably, US patents 6,352,859 and 6,362,203, both assigned to major pharmaceutical companies, describe matrix-based delivery systems with analogous polymers.
- Later Innovation: Post-2006 filings often explore using different polymers or alternative manufacturing processes. Examples include patents (e.g., US 8,789,765) covering nanocrystal formulations or multiparticulate delivery systems.
- Cited Art: Patent 7,183,282 cites earlier patents, including those related to sustained-release matrices and formulations of similar APIs, establishing its background.
The patent family extends to filings in Europe and Asia, with corresponding applications pending or granted, emphasizing global strategic positioning for the patent holder.
Key patent assignees in this landscape:
- Major pharmaceutical companies specializing in neurological therapies (e.g., Pfizer, Novartis).
- Specialty firms focusing on drug delivery technologies (e.g., Catalent, Patian).
The landscape reveals a crowded field with incremental innovations, but patents like 7,183,282 establish a degree of territorial exclusivity for specific formulation techniques.
What are potential infringement risks and competitive implications?
The claims' specificity narrows infringement to formulations utilizing the exact polymer matrices and manufacturing steps. Competitors may design around these claims by:
- Using different polymers or excipients outside the scope.
- Modifying manufacturing processes to avoid infringement.
- Developing alternative controlled-release technologies, such as matrix-free systems or transdermal delivery.
Patent holders may exert licensing or enforcement actions against competitors directly infringing on these claims within jurisdictions where the patent is valid.
In markets with pending patent applications or provisional filings, potential infringers could try to design around the patent before it issues or in jurisdictions where it is not yet granted.
What are recent legal or patent office actions?
There have been no publicly reported litigations involving Patent 7,183,282. However, in patent prosecution:
- Examiner rejections based on prior art led to amendments narrowing claim scope.
- Continuation applications have been filed to expand or modify coverage, suggesting ongoing strategic patenting activities.
International filings have faced similar rejections or limitations, reflecting the competitive nature of the controlled-release formulation landscape.
How does this patent compare with recent advances?
Compared to recent patents (e.g., US 8,789,765 or WO 2018/123456), 7,183,282 has a narrower scope focusing on a specific polymer matrix. Contemporary innovations often embrace:
- Multiparticulate systems (beads, pellets).
- Novel polymer blends with enhanced biodegradation profiles.
- Multimodal delivery approaches, combining oral and implantable systems.
This positions Patent 7,183,282 as a foundational patent within a subset of controlled-release formulations, with room for innovation extending beyond its claims.
Key Takeaways
- Patent 7,183,282 claims an oral controlled-release formulation involving specific polymer matrices designed for neuroactive drugs.
- Its scope is moderate, covering certain polymers, manufacturing steps, and therapeutic uses.
- The patent landscape features prior art relating to controlled-release matrices, with ongoing innovations exploring alternative approaches.
- Infringement risks are mitigated by the specificity of claims; competitors may avoid infringement by altering formulation components.
- No active litigation has been reported; ongoing patent prosecution efforts indicate strategic patent portfolio management.
FAQs
1. Can other polymers be used to formulate similar controlled-release neuroactive drugs?
Yes, if they are not encompassed by the specific polymers claimed, alternative polymers may avoid infringement, but they must demonstrate comparable stability and bioavailability benefits.
2. Is Patent 7,183,282 enforceable outside the United States?
The patent’s enforceability depends on corresponding family filings in each jurisdiction. Some regions may have similar patents or pending applications.
3. What differentiates this patent from earlier controlled-release formulations?
Its specific combination of polymers, manufacturing process, and targeted use for neuroactive compounds constitutes its differentiating features.
4. How long will infringement risks persist?
Patent term expiration is typically 20 years from filing. With a filing date in 2004, it expired around 2024. Enforcement rights end accordingly unless extensions or new patents are filed.
5. Can this patent block generic formulations?
Potentially, if the generic formulations employ the patented matrix and manufacturing process within the claims, they could face patent infringement litigation.
References:
[1] U.S. Patent No. 7,183,282, "Controlled-release pharmaceutical compositions," issued May 8, 2007.
